About Anabios
Anabios is a company based in San Diego (United States) founded in 2009. Anabios has raised $24.78 million across 12 funding rounds from investors including NIH, HHS and Ampersand Capital Partners. The company has 51 employees as of December 31, 2022. Anabios has completed 1 acquisition, including Cell Systems. Anabios offers products and services including Human Tissue and Cells, Functional Assays, Human Hepatocytes, and Human Precision-Cut Lung Slices. Anabios operates in a competitive market with competitors including Metrion Biosciences, Antibody Analytics, Quiver Bioscience, Zen-Bio and Pelago Bioscience, among others.
- Headquarter San Diego, United States
- Employees 51 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Anabios Corporation
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$24.78 M (USD)
in 12 rounds
-
Latest Funding Round
$6.5 M (USD), Series B
Jun 07, 2022
-
Investors
NIH
& 6 more
-
Employee Count
51
as on Dec 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Anabios
Anabios offers a comprehensive portfolio of products and services, including Human Tissue and Cells, Functional Assays, Human Hepatocytes, and Human Precision-Cut Lung Slices.
Provides human tissues for scientific research and drug testing.
Offers assays for evaluating drug effects on human tissues.
Specific human liver cells for research applications.
Human lung tissue slices for toxicity and efficacy studies.
People of Anabios
Unlock access to complete
Unlock access to complete
Funding Insights of Anabios
Anabios has successfully raised a total of $24.78M across 12 strategic funding rounds. The most recent funding activity was a Series B round of $6.5 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Anabios
Anabios has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, HHS and Ampersand Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Ampersand Capital Partners is focused on investments in healthcare and life sciences.
|
Locked | Locked | Locked | |
|
Early-stage investments in Italian tech and life sciences are targeted.
|
Locked | Locked | Locked | |
|
Angel Network for companies based in Southern California
|
Locked | Locked | Locked |
Investor details for Anabios
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Anabios
Anabios has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Cell Systems.
Investment portfolio details for Anabios
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Primary cells, culture media, and reagents are developed and manufactured.
|
Locked | Locked | 1989 | Locked |
Complete acquisition details for Anabios
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Anabios
Detailed financials for Anabios
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Anabios Comparisons
Peer comparison for Anabios
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Anabios
Anabios operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Metrion Biosciences, Antibody Analytics, Quiver Bioscience, Zen-Bio and Pelago Bioscience, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Ion channel screening and cardiac safety profiling services are provided.
|
|
| Locked | Locked | Locked |
Antibody analytics and characterization services are provided.
|
|
| Locked | Locked | Locked |
Developer of transformational medicines for neurological disorders
|
|
| Locked | Locked | Locked |
Cell-based solutions are provided to accelerate therapy discovery and development.
|
|
| Locked | Locked | Locked |
Drug-target interactions are quantified via specialized assay services.
|
Detailed competitors of Anabios
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Anabios
Complete news archive for Anabios
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Anabios
Anabios was founded in 2009 and raised its 1st funding round 2 years after it was founded.
Anabios is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Anabios is a funded company, having raised a total of $24.78M across 12 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Anabios is 51.
AnaBios provides contract research services for pre-clinical drug discovery which is entirely based on laboratory tests performed in living human tissues. It provides services for target selection and validation, lead optimisation, clinical candidate selection and clinical program de-risking through its proprietary Phase X platform. It offers its clients and partners full access to its assays and technologies that enable the study of ex-vivo human responses to drugs and the investigation of the molecular and functional basis of human physiology. The company focuses primarily on ex-vivo human studies for cardiovascular safety, pain and neurodegeneration. The company claims that its human-focused approach is a better predictor of safety and efficacy of drugs than the traditional in vitro or animal studies. The company also claims to have validated its technologies through its collaborations with pharma companies in US, Europe and Japan and has now initiated its own portfolio of drugs targeting CNS and Cardiovascular diseases. AnaBios has licensed a suite of patents for Nav1.7 sodium ion channel blockers from Purdue Pharma from which it will help in finding suitable candidates through its Phase X platform. The company also offers cardiac safety and toxicity and neurotoxicity services.
Anabios's top competitors include Metrion Biosciences, Quiver Bioscience and Zen-Bio.
Anabios offers Human Tissue and Cells, Functional Assays, Human Hepatocytes, and Human Precision-Cut Lung Slices.
Anabios has made 1 acquisition, including Cell Systems.
Anabios has 7 investors. Key investors include NIH, HHS, Ampersand Capital Partners, U.S. Food and Drug Administration, and Principia SGR.